Keros Therapeutics Investor Relations Material
Latest events
Status Update
Keros Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Keros Therapeutics Inc
Access all reports
Keros Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of novel treatments aimed at addressing unmet medical needs in hematological, pulmonary, and cardiovascular disorders. By leveraging cutting-edge science, Keros is focused on creating therapies that have the potential to significantly improve patient outcomes. The company's research and development efforts are grounded in the transformative potential of TGF-β (transforming growth factor-beta) science. It is headquartered in Lexington, Massachusetts, and its shares are listed on the NASDAQ.
Key slides for Keros Therapeutics Inc
Status Update
Keros Therapeutics Inc
Status Update
Keros Therapeutics Inc
Latest articles
)
The Rise and Fall of Wirecard
A look inside the Wirecard scandal, which took the company from the prestigious DAX 30 to insolvency through the largest accounting fraud in European history.
16 May 2025
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
Ticker symbol
KROS
Country
🇺🇸 United States